Ken Johnson

Equibles does not estimate personal net worth.

About Ken Johnson

Xeris Biopharma Holdings, Inc. reported in an 8-K filed February 24, 2025 that Ken Johnson retired as Senior Vice President, Global Development and Medical Affairs, effective April 1, 2025. The proxy statement of Xeris Biopharma Holdings, Inc. reports total compensation of $1,058,429 for Ken Johnson in fiscal 2024, including a base salary of $414,102. Disclosed compensation is on record for 2 fiscal years.

“On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the "Company") of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.”

Xeris Biopharma Holdings, Inc. Form 8-K, filed February 24, 2025 · Read the filing

Affiliation history

Xeris Biopharma Holdings, Inc. (XERS)
Proxy statement

Start not stated–2025-04-01

Company network

Xeris Biopharma Holdings, Inc.

XERS

Drug Manufacturers - Specialty & Generic · Healthcare

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2024	Xeris Biopharma Holdings, Inc. (XERS)	Senior Vice President, Global Development and Medical Affairs	$414,102	—	$430,500	—	$182,205	$31,622	$1,058,429
2023	Xeris Biopharma Holdings, Inc. (XERS)	Senior Vice President, Global Development and Medical Affairs	$398,174	—	$124,000	—	$191,738	$7,055	$720,967

Recent activity

Executive change Retired: Senior Vice President, Global Development and Medical Affairs Xeris Biopharma Holdings, Inc. (XERS)
2025-04-01